Vol 14, No 6 (December 31, 2025): Chinese Clinical Oncology

Enhancing audiometric surveillance in head and neck cancer patients undergoing cisplatin-based chemoradiation

Nonsurgical hepatocellular carcinoma treated with selective internal radiation therapy and personalized dosimetry: real-life data from French centers

Efficacy and safety of apatinib for the treatment of extensive-stage small cell lung cancer in Chinese patients: a single-arm systematic review and meta-analysis

Gleason score discrepancies between prostate biopsy and radical prostatectomy in prostate cancer patients: a retrospective single-center analysis

Identifying risk factors for refractory tyrosine kinase inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer

A comparison of outcomes for patients with localized pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy with and without radiation prior to curative-intent resection: an analysis of the National Cancer Database

Epidemiological trends and future projections of bladder and kidney cancer burden in China, 1990–2041: an ecological study

A bibliometric analysis of 2000–2024 on interventional therapy for liver cancer and tumor immune microenvironment

Temporal evolution of liver cancer etiology in China, 1990–2021: insights from the Global Burden of Disease Study 2021

Response to DNA-damaging agents and PARP inhibitors in ATM mutated metastatic colorectal cancer: case series

Radiation therapy in the era of precision medicine: a narrative review

Evaluation of cardiac markers in patients with breast cancer receiving antineoplastic treatment: a systematic review

Comparison of two validated nomograms in patients with localized soft tissue sarcoma of the extremities and trunk wall

Patient-reported outcomes in LITESPARK-005: a timely step toward patient-centered metrics in advanced renal cell carcinoma

Metronomic capecitabine plus aromatase inhibitor as initial therapy in HR-positive HER2-negative metastatic breast cancer: a low-cost and easily implementable option

ROS1 therapy among patients with advanced non-small cell lung cancer: an endless road to rediscover?